Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was based on the globa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Kumar, Shaji, Moreau, Philippe, Hari, Parameswaran, Mateos, Maria‐Victoria, Ludwig, Heinz, Shustik, Chaim, Masszi, Tamas, Spencer, Andrew, Hájek, Roman, Romeril, Kenneth, Avivi, Irit, Liberati, Anna M., Minnema, Monique C., Einsele, Hermann, Lonial, Sagar, Berg, Deborah, Lin, Jianchang, Gupta, Neeraj, Esseltine, Dixie‐Lee, Richardson, Paul G.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Haematological Malignancy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5574012/
https://ncbi.nlm.nih.gov/pubmed/28485007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14733
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados